Osteoinduction via residual growth factors

Osteoinduction via residual growth factors is a biological mechanism utilized in regenerative medicine, particularly in bone grafting and tissue engineering (Albrektsson & Johansson, 2001). It involves the recruitment of undifferentiated mesenchymal stem cells (MSCs) and their subsequent stimulation to differentiate into mature, bone-forming osteoblasts (Urist, 1965). This induction is mediated by bioactive proteins, primarily Bone Morphogenetic Proteins (BMPs), Transforming Growth Factor-beta (TGF-beta), and Fibroblast Growth Factors (FGFs), which are naturally sequestered within the bone matrix and preserved during the processing of materials like demineralized bone matrix (DBM) (Gruskin et al., 2012). These growth factors bind to specific transmembrane receptors on target cells, initiating signaling pathways such as the SMAD or MAPK cascades that upregulate osteogenic transcription factors like Runx2 (Wang et al., 2014). Clinically, this process is essential for successful bone repair in non-union fractures, spinal fusion surgeries, and maxillofacial reconstruction (Roberts & Rosenbaum, 2012). However, the efficacy of osteoinduction can vary based on the concentration and bioactivity of the residual factors, and excessive application can lead to adverse effects such as ectopic bone formation or localized inflammation.

Other names

Bone morphogenetic protein-mediated osteoinductionDBM-induced osteogenesisGrowth factor-mediated bone formationAutoinduction of bone

Induction of mesenchymal stem cell differentiation into osteoblasts through the activation of BMP and TGF-beta signaling pathways by endogenous growth factors preserved in bone graft matrices.